Treatment of age-related macular degeneration with Photodynamic Therapy (TAP)and Verteporfin in Photodynamic Therapy (VIP) study groups: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Meta-analysis of 2-year safety results in three randomized clinical trials
Treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report no. 4
Treatment of age-related macular degeneration with Photodynamic Therapy (TAP)and Verteporfin in Photodynamic Therapy (VIP) study groups: verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report no. 4 Retina 24 2004 1 12
Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (Visudyne)
M.T. Cahill, B.T. Smith, S. Fekrat Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (Visudyne) Am J Ophthalmol 134 2002 281 282
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with aspergillus species and other filamentous fungi: Maximum tolerated dose study
T.J. Walsh, J.L. Goodman, P. Pappas Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with aspergillus species and other filamentous fungi maximum tolerated dose study Antimicrob Agents Chemother 45 2001 3487 3496
Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction
J. Szebeni, L. Baranyi, S. Savay Liposome-induced pulmonary hypertension properties and mechanism of a complement-mediated pseudoallergic reaction Am J Physiol Heart Circ Physiol 279 2000 H1319 H1328